Clinical Trial

Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study

Study acronym: PASS-PD
Recruiting
View on ClinicalTrials.gov →
Summary
The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-01-21; most recent amendment 2025-09-16.
Status change: Not Yet Recruiting → Recruiting 2022-12-31
Trial Details
NCT Number NCT04724941
Lead Sponsor University Hospital Schleswig-Holstein
Collaborators: UCB Biopharma SRL, University of Kiel
Conditions Parkinson Disease
Enrollment 2,000 participants
Start Date 2021-06-01
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-22